ATA10002000A - Antigene zusammensetzung - Google Patents

Antigene zusammensetzung

Info

Publication number
ATA10002000A
ATA10002000A AT0100000A AT10002000A ATA10002000A AT A10002000 A ATA10002000 A AT A10002000A AT 0100000 A AT0100000 A AT 0100000A AT 10002000 A AT10002000 A AT 10002000A AT A10002000 A ATA10002000 A AT A10002000A
Authority
AT
Austria
Prior art keywords
composition
antique
inosin
cytosin
vaccine
Prior art date
Application number
AT0100000A
Other languages
English (en)
Other versions
AT410173B (de
Original Assignee
Cistem Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0100000A priority Critical patent/AT410173B/de
Application filed by Cistem Biotechnologies Gmbh filed Critical Cistem Biotechnologies Gmbh
Priority to CNB018107974A priority patent/CN1309418C/zh
Priority to PCT/EP2001/006437 priority patent/WO2001093903A1/en
Priority to AU2001262345A priority patent/AU2001262345A1/en
Priority to PT01960277T priority patent/PT1296713E/pt
Priority to HU0301229A priority patent/HU228264B1/hu
Priority to DK01960277T priority patent/DK1296713T3/da
Priority to AU2001281812A priority patent/AU2001281812B2/en
Priority to US10/297,555 priority patent/US8568742B2/en
Priority to JP2002501476A priority patent/JP5271471B2/ja
Priority to PCT/EP2001/006433 priority patent/WO2001093905A1/en
Priority to BRPI0111639A priority patent/BRPI0111639B8/pt
Priority to DE60109443T priority patent/DE60109443T2/de
Priority to DE2001600814 priority patent/DE60100814T2/de
Priority to AT01960277T priority patent/ATE249839T1/de
Priority to CZ2002-4168A priority patent/CZ304195B6/cs
Priority to RU2007103151A priority patent/RU2413520C2/ru
Priority to TR200302015T priority patent/TR200302015T4/xx
Priority to CA2411575A priority patent/CA2411575C/en
Priority to PL358982A priority patent/PL211036B1/pl
Priority to HK03109011.3A priority patent/HK1056678B/xx
Priority to EP20010960277 priority patent/EP1296713B1/de
Priority to ES01960277T priority patent/ES2206424T3/es
Priority to SK1815-2002A priority patent/SK287689B6/sk
Priority to US10/297,497 priority patent/US7148191B2/en
Priority to IL15295901A priority patent/IL152959A0/xx
Priority to RU2003100409A priority patent/RU2293573C2/ru
Priority to MXPA02012010A priority patent/MXPA02012010A/es
Priority to EP01936440A priority patent/EP1286695B1/de
Priority to AU8181201A priority patent/AU8181201A/xx
Priority to AT01936440T priority patent/ATE290880T1/de
Priority to KR20027016711A priority patent/KR100799788B1/ko
Priority to SI200130047T priority patent/SI1296713T1/xx
Publication of ATA10002000A publication Critical patent/ATA10002000A/de
Priority to IS6627A priority patent/IS1993B/is
Priority to IL152959A priority patent/IL152959A/en
Priority to ZA200209479A priority patent/ZA200209479B/en
Priority to NO20025835A priority patent/NO329492B1/no
Application granted granted Critical
Publication of AT410173B publication Critical patent/AT410173B/de
Priority to US11/609,777 priority patent/US20070218073A1/en
Priority to JP2013002571A priority patent/JP5908851B2/ja
Priority to US13/786,815 priority patent/US8945591B2/en
Priority to US14/585,740 priority patent/US9492537B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT0100000A 2000-06-08 2000-06-08 Antigene zusammensetzung AT410173B (de)

Priority Applications (41)

Application Number Priority Date Filing Date Title
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung
EP20010960277 EP1296713B1 (de) 2000-06-08 2001-06-07 Immunstimulierende oligodeoxynukleotide
AU2001262345A AU2001262345A1 (en) 2000-06-08 2001-06-07 Antigenic composition comprising a polycationic peptide and inosine and cytosine
PT01960277T PT1296713E (pt) 2000-06-08 2001-06-07 Oligodesoxinucleotidos imunoestimuladores
HU0301229A HU228264B1 (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
DK01960277T DK1296713T3 (da) 2000-06-08 2001-06-07 Immunstimulerende oligodeoxynukleotider
AU2001281812A AU2001281812B2 (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
US10/297,555 US8568742B2 (en) 2000-06-08 2001-06-07 Methods and compositions involving immunostimulatory oligodeoxynucleotides
JP2002501476A JP5271471B2 (ja) 2000-06-08 2001-06-07 免疫促進性オリゴデオキシヌクレオチド
PCT/EP2001/006433 WO2001093905A1 (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
BRPI0111639A BRPI0111639B8 (pt) 2000-06-08 2001-06-07 uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
DE60109443T DE60109443T2 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
DE2001600814 DE60100814T2 (de) 2000-06-08 2001-06-07 Immunstimulierende oligodeoxynukleotide
AT01960277T ATE249839T1 (de) 2000-06-08 2001-06-07 Immunstimulierende oligodeoxynukleotide
CZ2002-4168A CZ304195B6 (cs) 2000-06-08 2001-06-07 Imunostimulační farmaceutický přípravek
RU2007103151A RU2413520C2 (ru) 2000-06-08 2001-06-07 Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды
TR200302015T TR200302015T4 (tr) 2000-06-08 2001-06-07 İmüno-uyarıcı oligodeoksinükleotitler
SK1815-2002A SK287689B6 (sk) 2000-06-08 2001-06-07 Použitie molekuly oligodeoxynukleovej kyseliny na výrobu imunostimulačnej farmaceutickej kompozície a farmaceutický prípravok
PL358982A PL211036B1 (pl) 2000-06-08 2001-06-07 Zastosowanie cząsteczki immunostymulującego kwasu oligodezoksynukleinowego (ODN) i zawierająca ją kompozycja
HK03109011.3A HK1056678B (zh) 2000-06-08 2001-06-07 免疫刺激性寡脱氧核苷酸
CNB018107974A CN1309418C (zh) 2000-06-08 2001-06-07 免疫刺激性寡脱氧核苷酸
CA2411575A CA2411575C (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
PCT/EP2001/006437 WO2001093903A1 (en) 2000-06-08 2001-06-07 Antigenic composition comprising a polycationic peptide and inosine and cytosine
US10/297,497 US7148191B2 (en) 2000-06-08 2001-06-07 Antigenic composition
IL15295901A IL152959A0 (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
RU2003100409A RU2293573C2 (ru) 2000-06-08 2001-06-07 Иммуностимулирующие олигодезоксинуклеотиды
MXPA02012010A MXPA02012010A (es) 2000-06-08 2001-06-07 Oligodesoxinucleotidos inmunoestimulantes.
EP01936440A EP1286695B1 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
AU8181201A AU8181201A (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
AT01936440T ATE290880T1 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
KR20027016711A KR100799788B1 (ko) 2000-06-08 2001-06-07 면역촉진성 올리고디옥시뉴클레오티드
SI200130047T SI1296713T1 (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
ES01960277T ES2206424T3 (es) 2000-06-08 2001-06-07 Oligodesoxinucleotidos inmunoestimulantes.
IS6627A IS1993B (is) 2000-06-08 2002-11-18 Ónæmisörvandi fádeoxýkirni
IL152959A IL152959A (en) 2000-06-08 2002-11-20 Use of immunostimulatory oligodeoxynucleotides for the preparation of immunostimulatory pharmaceutical compositions
ZA200209479A ZA200209479B (en) 2000-06-08 2002-11-21 Immunostimulatory oligodeoxynucleotides.
NO20025835A NO329492B1 (no) 2000-06-08 2002-12-04 Anvendelse av immunstimulerende oligodeoksynukleinsyremolekyler for fremstilling av immunstimulerende, farmasoytiske sammensetninger og farmasoytiske sammensetninger som inneholder de samme.
US11/609,777 US20070218073A1 (en) 2000-06-08 2006-12-12 Antigenic composition
JP2013002571A JP5908851B2 (ja) 2000-06-08 2013-01-10 免疫促進性オリゴデオキシヌクレオチド
US13/786,815 US8945591B2 (en) 2000-06-08 2013-03-06 Methods and compositions involving immunostimulatory oligodeoxynucleotides
US14/585,740 US9492537B2 (en) 2000-06-08 2014-12-30 Methods and compositions involving immunostimulatory oligodeoxynucleotides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung

Publications (2)

Publication Number Publication Date
ATA10002000A true ATA10002000A (de) 2002-07-15
AT410173B AT410173B (de) 2003-02-25

Family

ID=3683921

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung
AT01936440T ATE290880T1 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01936440T ATE290880T1 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält

Country Status (7)

Country Link
US (2) US7148191B2 (de)
EP (1) EP1286695B1 (de)
AT (2) AT410173B (de)
AU (1) AU2001262345A1 (de)
DE (1) DE60109443T2 (de)
WO (1) WO2001093903A1 (de)
ZA (1) ZA200209479B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60044146D1 (de) * 1999-12-22 2010-05-20 Aventis Pasteur D ihre verwendungen
AU2001281812B2 (en) * 2000-06-08 2005-04-07 Valneva Austria Gmbh Immunostimulatory oligodeoxynucleotides
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
ATE398175T1 (de) * 2000-12-08 2008-07-15 Coley Pharmaceuticals Gmbh Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
CA2433561C (en) * 2001-01-03 2014-04-01 Willmar Poultry Company, Inc. Compositions including gram negative siderophore receptor proteins and methods of use
JP2004519453A (ja) * 2001-01-05 2004-07-02 インターツェル・アクチェンゲゼルシャフト ポリカチオン性化合物の用途
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
JP2005519035A (ja) * 2001-12-07 2005-06-30 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシヌクレオチド
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
WO2003073097A2 (en) * 2002-02-28 2003-09-04 Intercell Ag Methods for isolating ligands e.g. t cell epitopes
AU2003243161A1 (en) * 2002-04-24 2003-11-10 The Regents Of The University Of California Methods for stimulating tlr/irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses
EP1778186B1 (de) * 2002-07-03 2011-11-30 Oncovir, Inc. Verfahren zur herstellung von poly-iclc und seine verwendung
CA2484941A1 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
EP2402026A3 (de) 2002-09-13 2012-04-18 Intercell AG Verfahren zum Isolieren von Hepatitis-C-Virus-Peptiden
WO2004035618A2 (en) 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
AU2003297317A1 (en) * 2002-12-13 2004-07-09 Case Western Reserve University Defensin-inducing peptides from fusobacterium
SI1601770T1 (sl) 2003-03-04 2010-01-29 Intercell Ag Streptococcus pyogenes antigeni
ATE485056T1 (de) * 2003-03-24 2010-11-15 Intercell Ag Verbesserte impfstoffe
CN100355453C (zh) * 2003-03-24 2007-12-19 英特塞尔股份公司 改进的疫苗
DE602004024179D1 (de) 2003-03-31 2009-12-31 Intercell Ag Staphylococcus epidermidis antigene
EP2333114A1 (de) 2003-04-15 2011-06-15 Intercell AG S. pneumoniae Antigene
EP2275435A3 (de) 2003-05-07 2011-08-31 Intercell AG Streptococcus agalactiae antigene I + II
EP2327720A1 (de) 2003-05-30 2011-06-01 Intercell AG Enterokokken-Antigene
ES2395022T3 (es) * 2003-09-19 2013-02-07 Epitopix, Llc Polipéptidos de Campylobacter y sus métodos de uso
US20090060875A1 (en) * 2004-10-29 2009-03-05 Intercell Ag HCV Vaccines for Chronic HCV Patients
ES2586125T3 (es) 2005-02-14 2016-10-11 Epitopix, Llc Polipéptidos de Staphylococcus aureus y métodos de uso
CA2654271A1 (en) 2006-06-28 2008-01-03 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
EP2292646A3 (de) 2006-07-07 2011-06-08 Intercell AG Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
AU2007295927A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
CA2675379A1 (en) 2007-01-12 2008-07-17 Intercell Ag Protective proteins of s. agalactiae, combinations thereof and methods of using the same
KR20100051041A (ko) * 2007-03-07 2010-05-14 엔벤타 바이오파마슈티칼스 코퍼레이션 이중-가닥 봉쇄형 핵산 조성물
EP2489673A3 (de) 2007-05-02 2012-09-12 Intercell AG Klebsiella-Antigene
EP2012122A1 (de) 2007-07-06 2009-01-07 Medigene AG Strukturproteine von mutierten Parvoviren als Impfstoffe
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
EP2167530A2 (de) 2007-06-18 2010-03-31 Intercell AG Chlamydia-antigene
CA2700808C (en) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20110038888A1 (en) * 2008-01-10 2011-02-17 Peter Emtage Adjuvant compositions comprising poly-ic and a cationic polymer
JP2011514167A (ja) 2008-03-17 2011-05-06 インターセル アーゲー 肺炎連鎖球菌（Ｓ．ｐｎｅｕｍｏｎｉａｅ）に対して保護的なペプチドならびにそれに関連する組成物、方法、および使用
ES2524699T3 (es) 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
MX2010014026A (es) 2008-06-27 2011-02-15 Pfizer Composiciones adyuvantes novedosas.
WO2010089340A2 (en) 2009-02-05 2010-08-12 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
WO2010092176A2 (en) 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
NZ614557A (en) 2009-03-23 2015-03-27 Epitopix Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
WO2011042548A1 (en) 2009-10-09 2011-04-14 Sanofi-Aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP2319871A1 (de) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
EP2308896A1 (de) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
SMT201700124T1 (it) 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
WO2012031760A1 (en) 2010-09-08 2012-03-15 Medigene Ag Parvovirus mutated structural proteins comprising cross - protective b - cell epitopes of a hpv l2 protein as well as products and methods relating thereto
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
KR101943171B1 (ko) 2013-09-19 2019-01-29 조에티스 서비시즈 엘엘씨 유성 아쥬반트
DK3244920T5 (da) 2015-01-16 2024-10-07 Zoetis Services Llc Mund- og klovsyge-vaccine
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
EP3752184A1 (de) 2018-02-16 2020-12-23 2A Pharma AB Parvovirus-strukturprotein zur behandlung von autoimmunerkrankungen
EP3527223A1 (de) 2018-02-16 2019-08-21 2A Pharma AB Mutiertes parvovirus-strukturprotein
PH12021552736A1 (en) 2019-05-20 2022-07-11 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
EP3980056A4 (de) 2019-05-31 2023-03-29 Universidad De Chile Immunogene formulierung, die einen schutz gegen shiga-toxin-produzierende escherichia coli (stec) induziert
EP4058056A1 (de) 2020-10-07 2022-09-21 Valneva Sweden AB Cholera-impfstoffformulierung
JP2024522385A (ja) 2021-04-09 2024-06-19 ヴァルネヴァ エスイー ヒトメタニューモウイルスワクチン
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
US20250213667A1 (en) 2022-06-01 2025-07-03 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6801650D0 (pt) * 1968-08-20 1973-03-07 R Maes Processo para preparacao de complexos geradores de interferon
US3725545A (en) * 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
AU3891097A (en) * 1996-07-24 1998-02-10 Michelle M. Hanna Base-protected nucleotide analogs with protected thiol groups
EP1272215B1 (de) * 2000-04-14 2007-10-10 Intercell AG Modifizierte peptide enthaltende pharmazeutische präparationen
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung

Also Published As

Publication number Publication date
WO2001093903A1 (en) 2001-12-13
ATE290880T1 (de) 2005-04-15
AU2001262345A1 (en) 2001-12-17
AT410173B (de) 2003-02-25
US20030162738A1 (en) 2003-08-28
EP1286695A1 (de) 2003-03-05
US7148191B2 (en) 2006-12-12
DE60109443T2 (de) 2006-04-13
EP1286695B1 (de) 2005-03-16
ZA200209479B (en) 2003-11-21
DE60109443D1 (de) 2005-04-21
US20070218073A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
ATA10002000A (de) Antigene zusammensetzung
ATE500323T1 (de) Subtilisin-variante
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK1255826T3 (da) Automatisering af proteindesign for proteinbiblioteker
ATE380822T1 (de) Funf-helix protein
AU2001291687A1 (en) Polyammonium-polysiloxane compounds, methods for the production and use thereof
BR0311693A (pt) Sal de formato de o-desmetil-venlafaxina
SE0002102D0 (sv) Chemical compound
DE60310562D1 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
DK200000375U1 (da) Polypeptidsammensætninger med forbedret stabilitet.
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
CY1106056T1 (el) Παραγωγα 2-αμινο-2-αλκυλ-5-επτενοϊκου και επτυνοϊκου οξεος χρησιμα σαν αναστολεις συνθασης νιτρικου οξειδιου
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
ATE321853T1 (de) Humanische pellino-polypeptide
WO1999004011A3 (en) Hiv-1 group o antigens and uses thereof
EP1279677A4 (de) Gd3 mimetische peptide(05.11.01)
ATE342511T1 (de) Methode zur in vivo identifizierung von intrazellularen epitopen
ATE370160T1 (de) Peptide mit affinität zu gp120, und ihre verwendungen
TW200505943A (en) Polypeptide
ATE381351T1 (de) Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
ATE276277T1 (de) Monoklonale antikörper gegen antigene, die durch hämatopoietische helferzellen exprimiert werden
DE60113596D1 (de) Gasreformer zur Rückgewinnung von Wasserstoff
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
DE50109166D1 (de) Verfahren zur verbesserung der transfektionseffizienz

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee